Treatment of Human Embryonic Stem Cells with Different Combinations of Priming and Inducing Factors Toward Definitive Endoderm

Despite the enormous progress in studying definitive endoderm (DE) differentiation from human embryonic stem cells (hESCs), none of the reported protocols have produced a universal, cost-effective, and competent DE with the capability to further differentiate into endodermal derivatives. In this stu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Stem cells and development 2013-05, Vol.22 (9), p.1419-1432
Hauptverfasser: Tahamtani, Yasser, Azarnia, Mahnaz, Farrokhi, Ali, Sharifi-Zarchi, Ali, Aghdami, Nasser, Baharvand, Hossein
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1432
container_issue 9
container_start_page 1419
container_title Stem cells and development
container_volume 22
creator Tahamtani, Yasser
Azarnia, Mahnaz
Farrokhi, Ali
Sharifi-Zarchi, Ali
Aghdami, Nasser
Baharvand, Hossein
description Despite the enormous progress in studying definitive endoderm (DE) differentiation from human embryonic stem cells (hESCs), none of the reported protocols have produced a universal, cost-effective, and competent DE with the capability to further differentiate into endodermal derivatives. In this study, by using a 2-step differentiation strategy, we have treated hESCs for 1 day with “priming” small molecules (SM), [stauprimide, NSC-308848, rapamycin (Rapa), and/or CHIR] and for the next 3 days with “inducing” SM (LY294002, cymarin, IDE1, and/or IDE2) in conjunction with activin A. In the positive control group, we treated hESCs with Wnt3a (25 ng/mL) for 1 day and activin A (100 ng/mL; W/A100-A100) for the next 3 days. Gene expression analysis showed that treatment of hESCs with 100 nM Rapa and 50 ng/mL activin A (Rapa-A50) out of 25 combinations of factors gave rise to higher expressions of 2 DE-specific genes, SOX17 and FOXA2 . Similar results were obtained after treating 2 other hESC lines with this regimen. To investigate the competency of Rapa-A50-induced DE for further differentiation into endodermal derivatives, these cells and W/A100-A100-induced DE cells (positive control) were further differentiated into pancreatic progenitors (PP), then into pancreatic endocrine (PE) cells using 5 previously described differentiation protocols. Gene analysis of differentiated cells showed that the established protocols were insufficient to enable universal differentiation into PE, whereas Rapa-A50-induced DE cells were more competent for PP differentiation in a protocol-dependent manner. Additionally, Rapa-A50-induced DE had the capability to differentiate into hepatocyte-like cells (HLCs) as efficiently as W/A100-A100-induced DE. These data have indicated that hESCs primed with Rapa, and induced by a lower concentration of activin A, could lead to DE that had the capability to further differentiate into HLCs and PP cells, but not PE cells. Thus, current protocols for the differentiation of DE into PE still need additional study.
doi_str_mv 10.1089/scd.2012.0453
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1347259258</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1347259258</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-4db70eebea78096746d1f7bffbd0c15c8a2ab1da70e823429ae61b120223ee883</originalsourceid><addsrcrecordid>eNqFkDtvFDEURi0EIiFQ0iKXNLP4NWtPiTYbEikSSCz1yI9rMFrbwfYkSsNvZ6wNtFS-vjr3k76D0FtKNpSo6UO1bsMIZRsiRv4MndNxlIMauXjeZyEHzpQ8Q69q_UkI2zIlXqIzxpmYOJnO0e9DAd0ipIazx9dL1AnvoymPOQWLvzaIeAfHY8UPof3Al8F7KB3e5WhC0i3kVPvllxJiSN-xTg7fJLfY_rnStuVS8SE_6OLwJfiQQgv3gPfJZQclvkYvvD5WePP0XqBvV_vD7nq4_fzpZvfxdrCcyzYIZyQBMKClItNWiq2jXhrvjSOWjlZppg11eoUU44JNGrbUUEYY4wBK8Qv0_pR7V_KvBWqbY6h2LaYT5KXOlAvJxomNHR1OqC251gJ-vlu76fI4UzJ35fOqfO7K56585d89RS8mgvtH_3W8AvwE9LVO6RjWIqX9J_YPBiKPhQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1347259258</pqid></control><display><type>article</type><title>Treatment of Human Embryonic Stem Cells with Different Combinations of Priming and Inducing Factors Toward Definitive Endoderm</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Tahamtani, Yasser ; Azarnia, Mahnaz ; Farrokhi, Ali ; Sharifi-Zarchi, Ali ; Aghdami, Nasser ; Baharvand, Hossein</creator><creatorcontrib>Tahamtani, Yasser ; Azarnia, Mahnaz ; Farrokhi, Ali ; Sharifi-Zarchi, Ali ; Aghdami, Nasser ; Baharvand, Hossein</creatorcontrib><description>Despite the enormous progress in studying definitive endoderm (DE) differentiation from human embryonic stem cells (hESCs), none of the reported protocols have produced a universal, cost-effective, and competent DE with the capability to further differentiate into endodermal derivatives. In this study, by using a 2-step differentiation strategy, we have treated hESCs for 1 day with “priming” small molecules (SM), [stauprimide, NSC-308848, rapamycin (Rapa), and/or CHIR] and for the next 3 days with “inducing” SM (LY294002, cymarin, IDE1, and/or IDE2) in conjunction with activin A. In the positive control group, we treated hESCs with Wnt3a (25 ng/mL) for 1 day and activin A (100 ng/mL; W/A100-A100) for the next 3 days. Gene expression analysis showed that treatment of hESCs with 100 nM Rapa and 50 ng/mL activin A (Rapa-A50) out of 25 combinations of factors gave rise to higher expressions of 2 DE-specific genes, SOX17 and FOXA2 . Similar results were obtained after treating 2 other hESC lines with this regimen. To investigate the competency of Rapa-A50-induced DE for further differentiation into endodermal derivatives, these cells and W/A100-A100-induced DE cells (positive control) were further differentiated into pancreatic progenitors (PP), then into pancreatic endocrine (PE) cells using 5 previously described differentiation protocols. Gene analysis of differentiated cells showed that the established protocols were insufficient to enable universal differentiation into PE, whereas Rapa-A50-induced DE cells were more competent for PP differentiation in a protocol-dependent manner. Additionally, Rapa-A50-induced DE had the capability to differentiate into hepatocyte-like cells (HLCs) as efficiently as W/A100-A100-induced DE. These data have indicated that hESCs primed with Rapa, and induced by a lower concentration of activin A, could lead to DE that had the capability to further differentiate into HLCs and PP cells, but not PE cells. Thus, current protocols for the differentiation of DE into PE still need additional study.</description><identifier>ISSN: 1547-3287</identifier><identifier>EISSN: 1557-8534</identifier><identifier>DOI: 10.1089/scd.2012.0453</identifier><identifier>PMID: 23249309</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Activins - pharmacology ; Activins - physiology ; Antigens, Differentiation - genetics ; Antigens, Differentiation - metabolism ; Cell Differentiation - drug effects ; Cells, Cultured ; Embryonic Stem Cells - drug effects ; Embryonic Stem Cells - physiology ; Endoderm - cytology ; Endoderm - metabolism ; Gene Expression ; Glycogen - biosynthesis ; Hepatocyte Nuclear Factor 3-beta - genetics ; Hepatocyte Nuclear Factor 3-beta - metabolism ; Humans ; Liver - cytology ; Liver - metabolism ; Original Research Reports ; Pancreas - cytology ; Sirolimus - pharmacology ; SOXF Transcription Factors - genetics ; SOXF Transcription Factors - metabolism ; TOR Serine-Threonine Kinases - antagonists &amp; inhibitors</subject><ispartof>Stem cells and development, 2013-05, Vol.22 (9), p.1419-1432</ispartof><rights>2013, Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-4db70eebea78096746d1f7bffbd0c15c8a2ab1da70e823429ae61b120223ee883</citedby><cites>FETCH-LOGICAL-c337t-4db70eebea78096746d1f7bffbd0c15c8a2ab1da70e823429ae61b120223ee883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23249309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tahamtani, Yasser</creatorcontrib><creatorcontrib>Azarnia, Mahnaz</creatorcontrib><creatorcontrib>Farrokhi, Ali</creatorcontrib><creatorcontrib>Sharifi-Zarchi, Ali</creatorcontrib><creatorcontrib>Aghdami, Nasser</creatorcontrib><creatorcontrib>Baharvand, Hossein</creatorcontrib><title>Treatment of Human Embryonic Stem Cells with Different Combinations of Priming and Inducing Factors Toward Definitive Endoderm</title><title>Stem cells and development</title><addtitle>Stem Cells Dev</addtitle><description>Despite the enormous progress in studying definitive endoderm (DE) differentiation from human embryonic stem cells (hESCs), none of the reported protocols have produced a universal, cost-effective, and competent DE with the capability to further differentiate into endodermal derivatives. In this study, by using a 2-step differentiation strategy, we have treated hESCs for 1 day with “priming” small molecules (SM), [stauprimide, NSC-308848, rapamycin (Rapa), and/or CHIR] and for the next 3 days with “inducing” SM (LY294002, cymarin, IDE1, and/or IDE2) in conjunction with activin A. In the positive control group, we treated hESCs with Wnt3a (25 ng/mL) for 1 day and activin A (100 ng/mL; W/A100-A100) for the next 3 days. Gene expression analysis showed that treatment of hESCs with 100 nM Rapa and 50 ng/mL activin A (Rapa-A50) out of 25 combinations of factors gave rise to higher expressions of 2 DE-specific genes, SOX17 and FOXA2 . Similar results were obtained after treating 2 other hESC lines with this regimen. To investigate the competency of Rapa-A50-induced DE for further differentiation into endodermal derivatives, these cells and W/A100-A100-induced DE cells (positive control) were further differentiated into pancreatic progenitors (PP), then into pancreatic endocrine (PE) cells using 5 previously described differentiation protocols. Gene analysis of differentiated cells showed that the established protocols were insufficient to enable universal differentiation into PE, whereas Rapa-A50-induced DE cells were more competent for PP differentiation in a protocol-dependent manner. Additionally, Rapa-A50-induced DE had the capability to differentiate into hepatocyte-like cells (HLCs) as efficiently as W/A100-A100-induced DE. These data have indicated that hESCs primed with Rapa, and induced by a lower concentration of activin A, could lead to DE that had the capability to further differentiate into HLCs and PP cells, but not PE cells. Thus, current protocols for the differentiation of DE into PE still need additional study.</description><subject>Activins - pharmacology</subject><subject>Activins - physiology</subject><subject>Antigens, Differentiation - genetics</subject><subject>Antigens, Differentiation - metabolism</subject><subject>Cell Differentiation - drug effects</subject><subject>Cells, Cultured</subject><subject>Embryonic Stem Cells - drug effects</subject><subject>Embryonic Stem Cells - physiology</subject><subject>Endoderm - cytology</subject><subject>Endoderm - metabolism</subject><subject>Gene Expression</subject><subject>Glycogen - biosynthesis</subject><subject>Hepatocyte Nuclear Factor 3-beta - genetics</subject><subject>Hepatocyte Nuclear Factor 3-beta - metabolism</subject><subject>Humans</subject><subject>Liver - cytology</subject><subject>Liver - metabolism</subject><subject>Original Research Reports</subject><subject>Pancreas - cytology</subject><subject>Sirolimus - pharmacology</subject><subject>SOXF Transcription Factors - genetics</subject><subject>SOXF Transcription Factors - metabolism</subject><subject>TOR Serine-Threonine Kinases - antagonists &amp; inhibitors</subject><issn>1547-3287</issn><issn>1557-8534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkDtvFDEURi0EIiFQ0iKXNLP4NWtPiTYbEikSSCz1yI9rMFrbwfYkSsNvZ6wNtFS-vjr3k76D0FtKNpSo6UO1bsMIZRsiRv4MndNxlIMauXjeZyEHzpQ8Q69q_UkI2zIlXqIzxpmYOJnO0e9DAd0ipIazx9dL1AnvoymPOQWLvzaIeAfHY8UPof3Al8F7KB3e5WhC0i3kVPvllxJiSN-xTg7fJLfY_rnStuVS8SE_6OLwJfiQQgv3gPfJZQclvkYvvD5WePP0XqBvV_vD7nq4_fzpZvfxdrCcyzYIZyQBMKClItNWiq2jXhrvjSOWjlZppg11eoUU44JNGrbUUEYY4wBK8Qv0_pR7V_KvBWqbY6h2LaYT5KXOlAvJxomNHR1OqC251gJ-vlu76fI4UzJ35fOqfO7K56585d89RS8mgvtH_3W8AvwE9LVO6RjWIqX9J_YPBiKPhQ</recordid><startdate>20130501</startdate><enddate>20130501</enddate><creator>Tahamtani, Yasser</creator><creator>Azarnia, Mahnaz</creator><creator>Farrokhi, Ali</creator><creator>Sharifi-Zarchi, Ali</creator><creator>Aghdami, Nasser</creator><creator>Baharvand, Hossein</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130501</creationdate><title>Treatment of Human Embryonic Stem Cells with Different Combinations of Priming and Inducing Factors Toward Definitive Endoderm</title><author>Tahamtani, Yasser ; Azarnia, Mahnaz ; Farrokhi, Ali ; Sharifi-Zarchi, Ali ; Aghdami, Nasser ; Baharvand, Hossein</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-4db70eebea78096746d1f7bffbd0c15c8a2ab1da70e823429ae61b120223ee883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Activins - pharmacology</topic><topic>Activins - physiology</topic><topic>Antigens, Differentiation - genetics</topic><topic>Antigens, Differentiation - metabolism</topic><topic>Cell Differentiation - drug effects</topic><topic>Cells, Cultured</topic><topic>Embryonic Stem Cells - drug effects</topic><topic>Embryonic Stem Cells - physiology</topic><topic>Endoderm - cytology</topic><topic>Endoderm - metabolism</topic><topic>Gene Expression</topic><topic>Glycogen - biosynthesis</topic><topic>Hepatocyte Nuclear Factor 3-beta - genetics</topic><topic>Hepatocyte Nuclear Factor 3-beta - metabolism</topic><topic>Humans</topic><topic>Liver - cytology</topic><topic>Liver - metabolism</topic><topic>Original Research Reports</topic><topic>Pancreas - cytology</topic><topic>Sirolimus - pharmacology</topic><topic>SOXF Transcription Factors - genetics</topic><topic>SOXF Transcription Factors - metabolism</topic><topic>TOR Serine-Threonine Kinases - antagonists &amp; inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tahamtani, Yasser</creatorcontrib><creatorcontrib>Azarnia, Mahnaz</creatorcontrib><creatorcontrib>Farrokhi, Ali</creatorcontrib><creatorcontrib>Sharifi-Zarchi, Ali</creatorcontrib><creatorcontrib>Aghdami, Nasser</creatorcontrib><creatorcontrib>Baharvand, Hossein</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Stem cells and development</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tahamtani, Yasser</au><au>Azarnia, Mahnaz</au><au>Farrokhi, Ali</au><au>Sharifi-Zarchi, Ali</au><au>Aghdami, Nasser</au><au>Baharvand, Hossein</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Human Embryonic Stem Cells with Different Combinations of Priming and Inducing Factors Toward Definitive Endoderm</atitle><jtitle>Stem cells and development</jtitle><addtitle>Stem Cells Dev</addtitle><date>2013-05-01</date><risdate>2013</risdate><volume>22</volume><issue>9</issue><spage>1419</spage><epage>1432</epage><pages>1419-1432</pages><issn>1547-3287</issn><eissn>1557-8534</eissn><abstract>Despite the enormous progress in studying definitive endoderm (DE) differentiation from human embryonic stem cells (hESCs), none of the reported protocols have produced a universal, cost-effective, and competent DE with the capability to further differentiate into endodermal derivatives. In this study, by using a 2-step differentiation strategy, we have treated hESCs for 1 day with “priming” small molecules (SM), [stauprimide, NSC-308848, rapamycin (Rapa), and/or CHIR] and for the next 3 days with “inducing” SM (LY294002, cymarin, IDE1, and/or IDE2) in conjunction with activin A. In the positive control group, we treated hESCs with Wnt3a (25 ng/mL) for 1 day and activin A (100 ng/mL; W/A100-A100) for the next 3 days. Gene expression analysis showed that treatment of hESCs with 100 nM Rapa and 50 ng/mL activin A (Rapa-A50) out of 25 combinations of factors gave rise to higher expressions of 2 DE-specific genes, SOX17 and FOXA2 . Similar results were obtained after treating 2 other hESC lines with this regimen. To investigate the competency of Rapa-A50-induced DE for further differentiation into endodermal derivatives, these cells and W/A100-A100-induced DE cells (positive control) were further differentiated into pancreatic progenitors (PP), then into pancreatic endocrine (PE) cells using 5 previously described differentiation protocols. Gene analysis of differentiated cells showed that the established protocols were insufficient to enable universal differentiation into PE, whereas Rapa-A50-induced DE cells were more competent for PP differentiation in a protocol-dependent manner. Additionally, Rapa-A50-induced DE had the capability to differentiate into hepatocyte-like cells (HLCs) as efficiently as W/A100-A100-induced DE. These data have indicated that hESCs primed with Rapa, and induced by a lower concentration of activin A, could lead to DE that had the capability to further differentiate into HLCs and PP cells, but not PE cells. Thus, current protocols for the differentiation of DE into PE still need additional study.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>23249309</pmid><doi>10.1089/scd.2012.0453</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1547-3287
ispartof Stem cells and development, 2013-05, Vol.22 (9), p.1419-1432
issn 1547-3287
1557-8534
language eng
recordid cdi_proquest_miscellaneous_1347259258
source MEDLINE; Alma/SFX Local Collection
subjects Activins - pharmacology
Activins - physiology
Antigens, Differentiation - genetics
Antigens, Differentiation - metabolism
Cell Differentiation - drug effects
Cells, Cultured
Embryonic Stem Cells - drug effects
Embryonic Stem Cells - physiology
Endoderm - cytology
Endoderm - metabolism
Gene Expression
Glycogen - biosynthesis
Hepatocyte Nuclear Factor 3-beta - genetics
Hepatocyte Nuclear Factor 3-beta - metabolism
Humans
Liver - cytology
Liver - metabolism
Original Research Reports
Pancreas - cytology
Sirolimus - pharmacology
SOXF Transcription Factors - genetics
SOXF Transcription Factors - metabolism
TOR Serine-Threonine Kinases - antagonists & inhibitors
title Treatment of Human Embryonic Stem Cells with Different Combinations of Priming and Inducing Factors Toward Definitive Endoderm
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T09%3A52%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Human%20Embryonic%20Stem%20Cells%20with%20Different%20Combinations%20of%20Priming%20and%20Inducing%20Factors%20Toward%20Definitive%20Endoderm&rft.jtitle=Stem%20cells%20and%20development&rft.au=Tahamtani,%20Yasser&rft.date=2013-05-01&rft.volume=22&rft.issue=9&rft.spage=1419&rft.epage=1432&rft.pages=1419-1432&rft.issn=1547-3287&rft.eissn=1557-8534&rft_id=info:doi/10.1089/scd.2012.0453&rft_dat=%3Cproquest_cross%3E1347259258%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1347259258&rft_id=info:pmid/23249309&rfr_iscdi=true